Alemu Y, Degefa T, Bajiro M, Teshome G. Prevalence and intensity of soil-transmitted helminths infection among individuals in model and non-model households, South West Ethiopia: A comparative cross-sectional community based study. PLoS One. 2022; 17: e0276137. 34(6): 481-92.
Ansbro MR, Itkin Z, Chen L, Zahoranszky-Kohalmi G, Amaratunga C, Miotto O, Peryea T, Hobbs CV, Suon S, Sá JM, Dondorp AM, van der Pluijm RW, Wellems TE, Simeonov A, Eastman RT. Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Plasmodium falciparum Genotype. ACS Pharmacology and Translational Science. 2020; 3: 1144-57.
Antony HA, Parija SC. Antimalarial drug resistance: An overview. Trop Parasitol. 2016; 6: 30-41.
Assefa S, Shibeshi W. Drug resistance in African animal trypanosomes: A review. African Journal of Microbiology Research. 2018; 12.
Bushman M, Antia R, Udhayakumar V, de Roode JC. Within-host competition can delay evolution of drug resistance in malaria. PLoS Biol. 2018; 16: e2005712.
Capela R, Moreira R, Lopes F. An Overview of Drug Resistance in Protozoal Diseases. Int J Mol Sci. 2019; 20.
CDC. 2024. ‘About Ascariasis’. Centers for Disease Control and Prevention
CDC. 2024. ‘About Babesiosis’. Centers for Disease Control and Prevention
CDC. 2024. ‘About Cryptosporidiosis’. Centers for Disease Control and Prevention?
CDC. 2024. ‘About Hookworm’. Centers for Disease Control and Prevention
CDC. 2024. ‘About Leishmaniasis’. Centers for Disease Control and Prevention
CDC. 2024. ‘About Malaria’. Centers for Disease Control and Prevention
CDC. 2024. ‘About Sleeping Sickness’. Centers for Disease Control and Prevention
CDC. 2024. ‘About Toxoplasmosis’. Centers for Disease Control and Prevention
CDC. 2024. ‘About Whipworms’. Centers for Disease Control and Prevention
Chiu JE, Renard I, George S, Pal AC, Alday PH, Narasimhan S, Riscoe MK, Doggett JS, Ben Mamoun C. Cytochrome b Drug Resistance Mutation Decreases Babesia Fitness in the Tick Stages But Not the Mammalian Erythrocytic Cycle. J Infect Dis. 2022; 225: 135-45.
Conrad MD, Asua V, Garg S, Giesbrech, D, Niaré K, Smith S, Namuganga JF, Katairo T, Legac J, Crudale RM, Tumwebaze PK, Nsobya SL, Cooper RA, Kamya MR, Dorsey G, Bailey JA, Rosenthal PJ. Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. New England Journal of Medicine. 2023; 389: 722-32.
Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and Disease. Cell. 2016; 167: 610-24.
Dhar ED, Yadav AK, Basumatary G, Bez G. Anti-pinworm activity of novel coumarin-based trisubstituted methanes in Syphacia obvelata-infected mice. Parasitol Int. 2021; 85: 102425.
Dickie EA, Giordani F, Gould MK, Mäser P, Burri C, Mottram JC, Rao SPS, Barrett MP. New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story. Trop Med Infect Dis. 2020; 5.
Douanne N, Dong G, Amin A, Bernardo L, Blanchette M, Langlais D, Olivier M, Fernandez-Prada C. Leishmania parasites exchange drug-resistance genes through extracellular vesicles. Cell Rep. 2022; 40: 111121.
Dubey JP. Outbreaks of clinical toxoplasmosis in humans: five decades of personal experience, perspectives and lessons learned. Parasites and Vectors. 2021; 14: 263.
El-Sayad MH, El-Wakil ES, Moharam ZH, Abd El-Latif NF, Ghareeb MA, Elhadad H. Repurposing drugs to treat trichinellosis: in vitro analysis of the anthelmintic activity of nifedipine and Chrysanthemum coronarium extract. BMC Complement Med Ther. 2023; 23: 242.
El-Wakil ES, Abdelmaksoud HF, AbouShousha TS, Ghallab MMI. Evaluation of Annona muricata (Graviola) leaves activity against experimental trichinellosis: in vitro and in vivo studies. J Helminthol. 2021; 95: e53.
Eyayu T, Kiros T, Workineh L, Sema M, Damtie S, Hailemichael W, Dejen E, Tiruneh T. Prevalence of intestinal parasitic infections and associated factors among patients attending at Sanja Primary Hospital, Northwest Ethiopia: An institutional-based cross-sectional study. PLoS One. 2021; 16: e0247075.
Fairlamb AH, Horn D. Melarsoprol Resistance in African Trypanosomiasis. Trends Parasitol. 2018; 34: 481-92.
Geary TG, Woo K, McCarthy JS, Mackenzie CD, Horton J, Prichard RK, de Silva NR, Olliaro PL, Lazdins-Helds JK, Engels DA, Bundy DA. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int J Parasitol. 2010; 40: 1-13.
Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE. Malaria: progress, perils, and prospects for eradication. J Clin Invest. 2008; 118: 1266-76.
Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol. 2013; 114: 125-45.
Hasan MM, Stebbins EE, Choy RKM, Gillespie JR, de Hostos EL, Miller P, Mushtaq A, Ranade RM, Teixeira JE, Verlinde C, Sateriale A, Zhang Z, Osbourn DM, Griggs DW, Fan E, Buckner FS, Huston CD. Spontaneous Selection of Cryptosporidium Drug Resistance in a Calf Model of Infection. Antimicrob Agents Chemother. 2021; 65.
Hoffman JMCSL. 1996. Medical Microbiology. 4th edition. (University of Texas Medical Branch at Galceston).
Holbrook NR, Klontz EH, Adams GC, Schnittman SR, Issa NC, Bond SA, Branda JA, Lemieux JE. Babesia microti Variant With Multiple Resistance Mutations Detected in an Immunocompromised Patient Receiving Atovaquone Prophylaxis. Open Forum Infect Dis. 2023; 10: ofad097.
Idro R, Marsh K, John CC, Newton CR. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res. 2010; 68: 267-74.
Imran M, Khan SA, Alshammari MK, Alqahtani AM, Alanazi TA, Kamal M, Jawaid T, Ghoneim MM, Alshehri S, Shakeel F. Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis. Pharmaceuticals. 2022; (Basel) 15.
Iwanaga S, Kubota R, Nishi T, Kamchonwongpaisan S, Srichairatanakool S, Shinzawa N, Syafruddin D, Yuda M, Uthaipibull C. Genome-wide functional screening of drug-resistance genes in Plasmodium falciparum. Nat Commun. 2022; 13: 6163.
Jimenez Castro PD, Howell SB, Schaefer JJ, Avramenko RW, Gilleard JS, Kaplan RM. Multiple drug resistance in the canine hookworm Ancylostoma caninum: an emerging threat? Parasit Vectors. 2019; 12: 576.
Jones JL, Dubey JP. Waterborne toxoplasmosis–recent developments. Exp Parasitol. 2010; 124: 10-25.
Khan SM, Witola WH. Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: A comprehensive review. Front Cell Infect Microbiol. 2023; 13: 1115522.
Kim MS, Haney MJ, Zhao Y, Mahajan V, Deygen I, Klyachko NL, Inskoe E, Piroyan A, Sokolsky M, Okolie O, Hingtgen SD, Kabanov AV, Batrakova EV. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016; 12: 655-64.
Krücken J, Fraundorfer K, Mugisha JC, Ramünke S, Sifft KC, Geus D, Habarugira F, Ndoli J, Sendegeya A, Mukampunga C, Bayingana C, Aebischer T, Demeler J, Gahutu JB, Mockenhaupt FP, von Samson-Himmelstjerna G. Reduced efficacy of albendazole against Ascaris lumbricoides in Rwandan schoolchildren. Int J Parasitol Drugs Drug Resist. 2017; 7: 262-71.
Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003; 187: 1870-75.
Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe CV. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis. 2010; 202: 801-8.
Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006; 355: 1959-66.
Lim SS, Othman RY. Recent advances in Toxoplasma gondii immunotherapeutics. Korean J Parasitol. 2014; 52: 581-93.
Liu M, Ji S, Kondoh D, Galon EM, Li J, Tomihari M, Yanagawa M, Tagawa M, Adachi M, Asada M, Igarashi I, Iguchi A, Xuan X. Tafenoquine Is a Promising Drug Candidate for the Treatment of Babesiosis. Antimicrob Agents Chemother. 2021; 65: e0020421.
Maier AG, Matuschewski K, Zhang M, Rug M. Plasmodium falciparum. Trends Parasitol. 2019; 35: 481-82.
Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol. 2010; 617521.
Mann S, Frasca K, Scherrer S, Henao-Martínez AF, Newman S, Ramanan P, Suarez JA. A Review of Leishmaniasis: Current Knowledge and Future Directions. Curr Trop Med Rep. 2021; 8: 121-32.
Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol. 2005; 57: 1690-99.
Matamoros G, Rueda MM, Rodríguez C, Gabrie JA, Canales M, Fontecha G, Sanchez A. High Endemicity of Soil-Transmitted Helminths in a Population Frequently Exposed to Albendazole but No Evidence of Antiparasitic Resistance. Trop Med Infect Dis. 2019; 4.
Maxfield L, Crane JS. Leishmaniasis, In: StatPearls. StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Jonathan Crane declares no relevant financial relationships with ineligible companies.
Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio JJ, Pfrender M, Emrich S, Mohandas N, Dondorp AM, Wiest O, Haldar K. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015; 520: 683-87.
Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, et al., A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. N Engl J Med. 2016; 374: 2453-64.
Mharakurwa S, Matsena-Zingoni Z, Mudare N, Matimba C, Gara TX, Makuwaza A, Maponga G, Munyati S, Gwanzura L, Mutambu SL, Mason P, Kobayashi T, Midzi N, Moss WJ, Ippolito MM. Steep Rebound of Chloroquine-Sensitive Plasmodium falciparum in Zimbabwe. J Infect Dis. 2021; 223: 306-9.
Montazeri M, Mehrzadi S, Sharif M, Sarvi S, Tanzifi A, Aghayan SA, Daryani A. Drug Resistance in Toxoplasma gondii. Front Microbiol. 2018; 9: 2587.
Mordue DG, Wormser GP. Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection? J Infect Dis. 2019; 220: 442-7.
Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, Borrmann S, Mackinnon M, Nzila A. Chloroquine resistance before and after its withdrawal in Kenya. Malar J. 2009; 8: 106.
Mwanza S, Joshi S, Nambozi M, Chileshe J, Malunga P, Kabuya JB, Hachizovu S, Manyando C, Mulenga M, Laufer M. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malar J. 2016; 15: 584.
Nima MK, Mukherjee A, Sazed SA, Hossainey MRH, Phru CS, Johora FT, Safeukui I, Saha A, Khan AA, Marma ASP, et al., Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. mBio. 2022; 13: e0344421.
Patel P, Bharti PK, Bansal D, Ali NA, Raman RK, Mohapatra PK, Sehgal R, Mahanta J, Sultan AA, Singh N. Prevalence of mutations linked to antimalarial resistance in Plasmodium falciparum from Chhattisgarh, Central India: A malaria elimination point of view. Sci Rep. 2017; 7: 16690.
Perry D, Dixon K, Garlapati R, Gendernalik A, Poché D, Poché R. Visceral leishmaniasis prevalence and associated risk factors in the saran district of Bihar, India, from 2009 to July of 2011. Am J Trop Med Hyg. 2013; 88: 778-84.
Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA. 1988; 85: 9114-8.
Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, Pountain AW, Mwenechanya R, Papadopoulou B. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017; 11: e0006052.
Pradhan S, Schwartz RA, Patil A, Grabbe S, Goldust M. Treatment options for leishmaniasis. Clinical and Experimental Dermatology.2022; 47: 516-21.
Prayag K, Surve DH, Paul AT, Kumar S, Jindal AB. Nanotechnological interventions for treatment of trypanosomiasis in humans and animals. Drug Deliv Transl Res. 2020; 10: 945-61.
Rahmasari FV, et al., Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia. Malar J. 2022; 21(1): 354.
Rajapakse S, Chrishan Shivanthan M, Samaranayake N, Rodrigo C, Deepika Fernando S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 2013; 107: 162-169.
Rizk MA, AbouLaila M, El-Sayed SAE, Guswanto A, Yokoyama N, Igarashi I. Inhibitory effects of fluoroquinolone antibiotics on Babesia divergens and Babesia microti, blood parasites of veterinary and zoonotic importance. Infect Drug Resist. 2018; 11: 1605-15.
Robbins JR, Zeldovich VB, Poukchanski A, Boothroyd JC, Bakardjiev AI. Tissue barriers of the human placenta to infection with Toxoplasma gondii. Infect Immun. 2012; 80: 418-28.
Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, Socheat D, Ariey F, Wongsrichanalai C.Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J. 2009; 8: 10.
Roose, S., Avramenko, R.W., Pollo, S.M.J., Wasmuth, J.D., Ame, S., Ayana, M., Betson, M., Cools, P., Dana, D., Jones, B.P., et al., Characterization of the β-tubulin gene family in Ascaris lumbricoides and Ascaris suum and its implication for the molecular detection of benzimidazole resistance. PLoS Negl Trop Dis. 2021; 15: e0009777.
Runtuwene LR, Tuda JSB, Mongan AE, Makalowski W, Frith MC, Imwong M, Srisutham S, Nguyen Thi LA, Tuan NN, Eshita Y, Maeda R, Yamagishi J, Suzuki Y. Nanopore sequencing of drug-resistance-associated genes in malaria parasites, Plasmodium falciparum. Sci Rep. 2018; 8: 8286.
Saha B, Pai K, Sundar S, Bhattacharyya M, Bodhale NP. The drug resistance mechanisms in Leishmania donovani are independent of immunosuppression. Cytokine. 2021; 145: 155300. Salam N, Azam S. Prevalence and distribution of soil-transmitted helminth infections in India. BMC Public Health. 2017; 17: 201.
Silva MG, Villarino NF, Knowles DP, Suarez CE. Assessment of Draxxin(®) (tulathromycin) as an inhibitor of in vitro growth of Babesia bovis, Babesia bigemina and Theileria equi. Int J Parasitol Drugs Drug Resist. 2018; 8: 265-70.
Sundar S, Agrawal N, Singh B. Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development. Expert Opin Drug Metab Toxicol. 2019; 15: 595-612.
Sweeny AR, Clerc M, Pontifes PA, Venkatesan S, Babayan SA, Pedersen AB. Supplemented nutrition decreases helminth burden and increases drug efficacy in a natural host-helminth system. Proc Biol Sci. 2021; 288: 20202722.
Talmi-Frank D, Nasereddin A, Schnur LF, Schönian G, Töz SO, Jaffe CL, Baneth G. Detection and identification of old world Leishmania by high resolution melt analysis. PLoS Negl Trop Dis. 2010; 4: e581.
Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A. 1997; 94: 13944-9.
Tuvshintulga B, Sivakumar T, Yokoyama N, Igarashi I. Development of unstable resistance to diminazene aceturate in Babesia bovis. Int J Parasitol Drugs Drug Resist. 2019; 9: 87-92.
Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, Krause PJ, Yokoyama N, Igarashi I. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. J Infect Dis. 2020; 222: 1027-36.
van der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm? Trends in Parasitology. 2021; 37: 15-24.
van der Pluijm, RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, Jittamala P, Hanboonkunupakarn B, Chutasmit K, et al., Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019; 19: 952-61.
Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE, Lehane AM, Fidock DA. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016; 7: 11553.
Venturelli A, Tagliazucchi L, Lima C, Venuti F, Malpezzi G, Magoulas GE, Santarem N, Calogeropoulou T, Cordeiro-da-Silva A, Costi MP. Current Treatments to Control African Trypanosomiasis and One Health Perspective. Microorganisms. 2022; 10.
Voumbo-Matoumona DF, Kouna LC, Madamet M, Maghendji-Nzondo S, Pradines B, Lekana-Douki JB. Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014. Infect Drug Resist. 2018; 11: 1329-38.
Wei XY, Gao Y, Lv C, Wang W, Chen Y, Zhao Q, Gong QL, Zhang XX. The global prevalence and risk factors of Toxoplasma gondii among foxes: A systematic review and meta-analysis. Microb Pathog. 2021; 150: 104699.
Wendt S, Trawinski H, Schubert S, Rodloff AC, Mössner J, Lübbert C. The Diagnosis and Treatment of Pinworm Infection. Dtsch Arztebl Int. 2019; 116: 213-9.
WHO. 2023. ‘Leishmaniasis’. World Health Organization
WHO. 2023. ‘Malaria’. World Health Organization
WHO. 2023. ‘Trypanosomiasis, human African (sleeping sickness)’ World Health Organization
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin Infect Dis. 2010; 50: 381-6.